Medical researchers and healthcare systems generate vast amounts of data every single day. If linked up and harnessed, it could revolutionise medicines development and healthcare. However, most of this ‘big data’ remains in silos, inaccessible to most researchers, its potential untapped. Meanwhile digital technologies and wearable devices offer new and more efficient ways of gathering data, but question marks remain about how to address issues like patient privacy and how these devices fit in with patients’ lives.
IMI has had ‘big data’ projects since its creation. IMI’s Big Data for Better Outcomes programme is addressing the technical, legal and ethical issues that currently prevent researchers from making full use of the data that is out there. What’s more, the projects are putting ‘big data’ principles into practice to advance research in the fields of cardiovascular disease, haematological malignancies (blood cancers), Alzheimer’s disease, and prostate cancer. IMI also boasts a number of projects working on health-related mobile and digital technologies.
#BigDataforbloodcancer | Big Data accelerate better and faster treatment for Patients with Hematologic Malignancies
The HARMONY Alliance is a European Public–Private Partnership for Big Data in Hematology that is capturing and mining Big Data on Hematologic Malignancies. Both projects of the HARMONY Alliance, HARMONY and HARMONY PLUS, are funded by the Innovatie Medicines Initiative (IMI).
HARMONY unites more than 100 organizations from 18 European countries, such as medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies. HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. Data are stored in HARMONY’s Big Data Platform, which has already identified over 70,000 anonymized patient records, making it one of the largest databases of its kind. Leading research teams are currently using this wealth of information to answer critical questions about hematologic malignancies that cannot be addressed with other methods.
Receive the latest news. Click here to subscribe!